Administration of combined contraceptive containing dienogest and ethinyl estradiol for endometriosis

Abstract

The article tells about the use of a combined contraceptive preparation containing the novel progestogen - dienogest - in conservative antirecurrent treatment of endometriosis. According to current concepts, endometriosis is a chronical dishormonal, immunodependent, multifactorial, genetically determined disease which manifests itself in the growth and presence of endometrioid heterotopias in the uterus. While accurate diagnosis and ablation of heterotopias require surgery, for subsequent treatment, doctor's toolkit offers a multitude of medicines the effects of which are on the whole described by the following: fight against manifestations of endometriosis, inhibition of the progression of the process, reduction of the disease recurrence, and improving the quality of life of patients. Pharmacotherapy of endometriosis should be effective and safe. Dienogest demonstrated properties comparable to those of gonadotropin-releasing hormone agonists, especially for early clinical manifestations of endometriosis. The combined contraceptive containing ethinylestradiol and dienogest is best suited for long-term (several months) treatment of endometriosis under a cyclic or continuous regimen.